Dec 14,2022

Electronic Skin Patches Sales to Reach USD 29 Billion by 2027, Next-Gen Electronic Skin Patches to Witness Tremendous Demand. Abbott, Dexcom, GE, and Philips Set to Capatilize the Opportunity - Arizton

According to latest research report, the electronic skin patches market will grow at a CAGR of 20.17% during 2021-2027. A few exciting start-ups and universities are working to bring advanced electronic skin sensor patches into the market. For instance, XSENSIO SA has developed next-generation wearable devices to track biochemical information on the wearer's skin surface. Application areas of this technology includes diabetes management, remote patient monitoring, cardiovascular monitoring and others.

#rpm

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Tandem Diabetes Care to buy Swiss insulin pump developer AMF Medical

Tandem Diabetes Care announced Wednesday it has entered into an agreement to buy AMF Medical SA, a Swiss company developing a patch insulin pump. The Sigi Patch Pump, which is not yet commercially available, is a rechargeable patch that uses pre-filled insulin cartridges. The company said it would be compatible with automated insulin delivery systems.

COLLABORATION MERGERS & ACQUISITION

#product & service

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 16,2022

Roche expands access to diabetes care for financially disadvantaged in local communities

Roche today announced that it has partnered with charity organisation, Diabetes Singapore, to launch the Access to Care programme in support of people with diabetes from lower-income groups who need a helping hand with regular self-monitoring of blood glucose (SMBG), a move that is crucial to keep their blood glucose levels in range. The programme is a step towards making structured SMBG more accessible and affordable to help ease the financial burden on lower-income groups in Singapore, as blood glucose monitoring supplies are recurring out-of-pocket expenses.

COLLABORATION PARTNERSHIP

#institution

#bgm

View Analyst & Ambassador Comments
Go to original news
Dec 19,2022

Amalgam Rx Enhances Partnership with Novo Nordisk

Amalgam Rx, Inc. is announcing the expansion of its global agreement with Novo Nordisk for the commercialization of Dose Check. Dose Check is a digital insulin initiation and titration app developed to help people with type 2 diabetes using basal insulin. The new agreement bolsters the existing partnership and product suite between Novo Nordisk and Amalgam by incorporating and integrating with connected insulin delivery devices, continuous glucose monitors, and electronic health records (EHRs). Novo Nordisk is also making an equity investment in Amalgam.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 20,2022

ABBOTT TO PRESENT AT J.P. MORGAN HEALTHCARE CONFERENCE

Abbott will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 20,2022

Embecta stock slides on mixed Q4 results

Embecta registered a significant bottom-line skid into the red on a sales decline of 8.7%. This time last year — as the diabetes arm of BD — Embecta posted profits of $97.1 million for the quarter. However, Embecta noted that last year’s numbers do not purport to reflect its performance if it were a standalone company. The Parsippany, New Jersey-based company posted losses of $17.2 million. That amounts to 30¢ per share on sales of $274.6 million for the three months ended Sept. 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Dec 20,2022

BIOCORP Announces Its Certification to the New European Medical Device Regulation

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received the EU production quality assurance certificate according to the new regulation for non-sterile medical devices with measurement function for drug administration.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Dec 21,2022

FDA clearance for Dexcom G7 marks a ‘huge leap’ forward, COO Jake Leach says

Dexcom (Nasdaq:DXCM) CEO Kevin Sayer told Drug Delivery Business News that its next-generation CGM would be “wonderful.” At the time, he said enthusiasm over the Dexcom G7 sat at an all-time high. The Dexcom G7 demonstrated exciting results in glucose monitoring in a number of clinical trials. One study highlights its accuracy, and another demonstrates success with pediatric users. Dexcom announced its international rollout for G7 in October. The system won CE mark in March.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 21,2022

Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe

Abbott today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab. Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data.

PRODUCT

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Dec 21,2022

Digital Diabetes Management Market Size to Reach USD 37.8 Billion in 2030 | Emergen Research

The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research. Increasing prevalence of diabetes and obesity around the world, rising demand for medical devices and management apps such glucose tracking apps and wearables as well as advent of technologically innovative cloud-based digital tools and solutions are some key factors driving digital diabetes management market revenue growth. Chronic illnesses with a high prevalence and significant social and economic costs are metabolic diseases like diabetes mellitus (DM) and obesity.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES